<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704314</url>
  </required_header>
  <id_info>
    <org_study_id>EK: 258/2002</org_study_id>
    <nct_id>NCT00704314</nct_id>
  </id_info>
  <brief_title>Does Simvastatin Affect Insulin Sensitivity in Dyslipidemic Type 2 Diabetic Patients?</brief_title>
  <official_title>Effects of High Dose Simvastatin Therapy on Glucose Metabolism and Ectopic Lipid Deposition in Non-Obese Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Austrian Science Fund (FWF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Foundation for the Study of Diabetes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EU grant</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aimed to address the issue whether statins affect insulin resistance. To this end, we
      combined the available state-of-the art technology for detailed assessment of both whole-body
      and tissue specific insulin sensitivity in vivo in humans (euglycemic-hyperinsulinemic clamp,
      stable isotope [6,6-2H2]glucose dilution technique, proton nuclear magnetic resonance
      spectroscopy - 1H MRS - of liver and skeletal muscle). Outcome measures were determined
      before and after 8 weeks therapy with 80 mg Simvastatin in hypercholesterolemic patients with
      type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ectopic lipid deposition in liver and muscle</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Diabetes</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simvastatin therapy, 80 mg/d for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, one pill daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>80 mg Simvastatin daily for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zocord</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo was identical in appearance and was provided by the same manufacturer</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic patients with known duration of disease: 3-10 years

          -  Age: 35-75 years

          -  BMI&lt;32 kg/m2

          -  Hypercholesterolemia: fasting serum low density lipoprotein (LDL)

          -  Cholesterol concentration &lt; 4.16 mmol/L (&lt;160 mg/dl)

          -  Normotriglyceridemia: fasting plasma triglyceride concentration &lt; 2.75 mmol/L (250
             mg/dl)

          -  Creatinine levels &lt; 1.8 mg /dl

          -  Liver transaminases &lt; 20% over the upper limit with no active liver disease and CK &lt;
             50% above the upper limit

          -  Blood pressure less than 160/100 mmHg were accepted as eligible for enrollment

        Exclusion Criteria:

          -  Hypertension, cardiovascular disease or metabolic diseases other than T2DM as
             determined by medical history, physical examination and routine laboratory tests

          -  Alcohol consumption (more than 10 drinks/week)

          -  Poor glycemic control (HbA1c&lt;9%)

          -  Patients requiring insulin, patients with type 1 diabetes

          -  Patients taking any medicine known to interfere with metabolism of statins or with
             insulin sensitivity as summarized in an exclusionary drug table

          -  Patients receiving any hypolipidemic medication or diet during the last 2 months
             before enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Waldhäusl, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2008</study_first_posted>
  <last_update_submitted>June 23, 2008</last_update_submitted>
  <last_update_submitted_qc>June 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Werner Waldhäusl, Prof. Dr. Michael Roden</name_title>
    <organization>Hanusch Hospital, 1. Medical Department, Vienna Austria</organization>
  </responsible_party>
  <keyword>Insulin resistance</keyword>
  <keyword>Statins</keyword>
  <keyword>Muscle and liver triglycerides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

